Document Classification

Section Type: RESULTS

Text: During a median follow-up of 2 years (range up to 5 years), rates of the primary trial endpoint were 1. 18, 0. 86, and 0. 44 per 100 person-years in the placebo group (n = 8, 150) and rosuvastatin groups without LDL-C < 50 mg/dl (n = 4, 000) or with LDL-C < 50 mg/dl (n = 4, 154), respectively (fully-adjusted hazard ratio : 0. 76 ; 95 % confidence interval : 0. 57 to 1. 00 for subjects with no LDL-C < 50 mg/dl vs. placebo and 0. 35, 95 % confidence interval : 0. 25 to 0. 49 for subjects attaining LDL-C < 50 mg/dl ; p for trend < 0. 0001).